ECSP11010809A - Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad - Google Patents

Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad

Info

Publication number
ECSP11010809A
ECSP11010809A EC2011010809A ECSP11010809A ECSP11010809A EC SP11010809 A ECSP11010809 A EC SP11010809A EC 2011010809 A EC2011010809 A EC 2011010809A EC SP11010809 A ECSP11010809 A EC SP11010809A EC SP11010809 A ECSP11010809 A EC SP11010809A
Authority
EC
Ecuador
Prior art keywords
treatment
pirazolo
pirimidin
obesity
diabetes
Prior art date
Application number
EC2011010809A
Other languages
English (en)
Inventor
Michael James Waring
Robert Davies
Leonie Campbell
Roger John Butlin
Graeme Richard Robb
Stuart Norman Lile Bennett
Peter Gustaf Bonn
Mikael Dan Brink
Jonas Rickard Fagerhag
Ulrik Jurva
Helen Claire Pointon
Rolf Peter Walker
Christer Ralf Westerlund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP11010809A publication Critical patent/ECSP11010809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula (I), es útil en el tratamiento o prevención de una enfermedad o afección médica mediada por glucoquinasa (GLK o GK), que conduce a una reducción del umbral de glucosa para la secreción de insulina
EC2011010809A 2008-08-04 2011-02-04 Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad ECSP11010809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8591908P 2008-08-04 2008-08-04
US16804809P 2009-04-09 2009-04-09

Publications (1)

Publication Number Publication Date
ECSP11010809A true ECSP11010809A (es) 2011-03-31

Family

ID=41563374

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010809A ECSP11010809A (es) 2008-08-04 2011-02-04 Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad

Country Status (23)

Country Link
US (1) US8143263B2 (es)
EP (1) EP2324028A2 (es)
JP (1) JP2011529955A (es)
KR (1) KR20110052676A (es)
CN (1) CN102171213A (es)
AR (1) AR072900A1 (es)
AU (1) AU2009278929B2 (es)
BR (1) BRPI0917589A2 (es)
CA (1) CA2732165A1 (es)
CL (1) CL2011000249A1 (es)
CO (1) CO6351730A2 (es)
CR (1) CR20110065A (es)
DO (1) DOP2011000047A (es)
EA (1) EA201100097A1 (es)
EC (1) ECSP11010809A (es)
IL (1) IL210778A0 (es)
MX (1) MX2011001333A (es)
PE (1) PE20110568A1 (es)
SV (1) SV2011003829A (es)
TW (1) TW201011026A (es)
UY (1) UY32032A (es)
WO (1) WO2010015849A2 (es)
ZA (1) ZA201101663B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076220A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103450124B (zh) * 2013-08-30 2016-03-09 江苏九九久科技股份有限公司 决奈达隆合成方法
EP3294062A4 (en) * 2015-05-14 2019-02-13 The Regents of the University of California Brassinosteroid mimetics
TWI724077B (zh) * 2015-12-16 2021-04-11 日商日本曹達股份有限公司 芳基唑化合物及有害生物防除劑
CN106749264A (zh) * 2016-11-13 2017-05-31 曹艳 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途
CN106749263A (zh) * 2016-11-13 2017-05-31 曹艳 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途
CN106749265A (zh) * 2016-11-13 2017-05-31 曹艳 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途
CN106361753A (zh) * 2016-11-13 2017-02-01 曹艳 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途
EP3357928B1 (en) 2017-02-03 2021-01-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel dyes with phosphinic acid, phosphinate, phosphonate and phosphonamidate substituents as auxochromic groups and methods for preparing the same
CN108033966A (zh) * 2018-01-05 2018-05-15 天津药明康德新药开发有限公司 7-叔丁基3-乙基8-甲基5,6二氢三唑并吡嗪3,7(8h)二甲酸基酯的合成方法
US12168643B2 (en) 2019-06-19 2024-12-17 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
CN113185520A (zh) * 2021-04-28 2021-07-30 山东鲁抗医药股份有限公司 替格瑞洛杂质b及其制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (fr) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
CS173097B1 (es) 1972-12-01 1977-02-28
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS59139357A (ja) 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
DE3822449A1 (de) 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
ES2281090T3 (es) * 1996-11-06 2007-09-16 Basilea Pharmaceutica Ag Derivados de vinilpirrolidona-cefalosporina.
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
EP0910565A1 (en) * 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
KR20010014183A (ko) * 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
WO1999024415A1 (en) 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Retinoid receptor agonists
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
CA2318731C (en) * 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
DE19816780A1 (de) 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
AU1917201A (en) 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Amide therapeutics and methods for treating inflammatory bowel disease
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
CN1176915C (zh) 2000-05-03 2004-11-24 霍夫曼-拉罗奇有限公司 炔基苯基芳香杂环的菊糖激酶激活剂
WO2002042270A1 (en) 2000-11-22 2002-05-30 Yamanouchi Pharmaceutical Co., Ltd. Substituted benzene derivatives or salts thereof
DE60117059T2 (de) 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
WO2002051397A1 (en) 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
EP1357116A4 (en) 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN101284773A (zh) 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
DE10161765A1 (de) 2001-12-15 2003-07-03 Bayer Cropscience Gmbh Substituierte Phenylderivate
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
EP2385040A1 (en) * 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
BRPI0507734A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
ES2322709T3 (es) 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP2546234A1 (en) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CA2605738C (en) 2005-04-25 2013-10-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel azaheterocyclic compounds as kinase inhibitors
WO2006125958A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20090105263A1 (en) 2005-09-16 2009-04-23 Peter William Rodney Caulkett Heterobicyclic compounds as glucokinase activators
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
BRPI0721143A2 (pt) 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
AU2009278929B2 (en) 2012-07-05
WO2010015849A3 (en) 2010-04-01
BRPI0917589A2 (pt) 2015-11-17
ZA201101663B (en) 2011-11-30
MX2011001333A (es) 2011-03-15
AU2009278929A8 (en) 2011-03-10
AU2009278929A1 (en) 2010-02-11
JP2011529955A (ja) 2011-12-15
EA201100097A1 (ru) 2011-10-31
DOP2011000047A (es) 2011-02-28
US20100093757A1 (en) 2010-04-15
AR072900A1 (es) 2010-09-29
CR20110065A (es) 2011-05-10
CO6351730A2 (es) 2011-12-20
US8143263B2 (en) 2012-03-27
UY32032A (es) 2010-03-26
CA2732165A1 (en) 2010-02-11
WO2010015849A2 (en) 2010-02-11
IL210778A0 (en) 2011-03-31
CL2011000249A1 (es) 2011-07-15
TW201011026A (en) 2010-03-16
KR20110052676A (ko) 2011-05-18
CN102171213A (zh) 2011-08-31
PE20110568A1 (es) 2011-09-07
EP2324028A2 (en) 2011-05-25
SV2011003829A (es) 2011-07-01

Similar Documents

Publication Publication Date Title
ECSP11010809A (es) Derivados de pirazolo[3,4-d]pirimidin-4-il y sus usos en el tratamiento de diabetes y obesidad
GEP20146120B (en) Sglt-2 inhibitor for treating type i diabetes mellitus, type ii diabetes mellitus, impaired glucose tolerance or hyperglycemia
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
NO20084919L (no) Oksadiazolidindionforbindelse
CO6361917A2 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
CR10564A (es) Compuestos cíclicos fusionados
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
MX2012001339A (es) Compuestos inhibidores de apaf-1.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
MX387086B (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas
NZ603614A (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
UY32550A (es) "(2s)-2-[1-(2,6-diclorofenil)pirazolo[4, 5-e]pirimidin-4-il] oxi-3-(3-hidroxiazetidin-1-il) -n-(5-metilpirazin-2-il) propanamida
IN2012DN00977A (es)
AR076221A1 (es) Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
CU20110034A7 (es) Agentes terapéuticos 414